Shares of TG Therapeutics slumped after the company's second-quarter profit missed analyst estimates. The stock was down 17% at $29.22 in early trading. Shares are now 3% lower than where they had ...

Bullish, which also owns the crypto-focused media company CoinDesk, said it would have more than 139.5 million shares outstanding after the IPO, assuming an exercise of the overallotment option, for a ...

Bruker said it faced challenging market conditions, driven by tariffs and harmful currency values.

All large cryptocurrencies were up during U.S. morning trading on Monday, with XRP XRPUSD +4.45% seeing the biggest change, climbing 4.45% to $3.05.

AMD’s stock rally looks overdone to analysts at Jefferies, who are expecting some pullback after the company reports earnings ...

Nomura's Charlie McElligott is looking prescient once again, after correctly anticipating a replay of last summer's "growth scare." But according to his latest note, for any selloff to gain momentum ...

U.S. stocks opened higher Monday, bouncing after a Friday drop that left the S&P 500 and Nasdaq with their biggest weekly losses since late May. Friday's weakness followed a weaker-than-expected July ...

Exchange operator Miami International Holdings on Monday said it plans to sell 15 million shares at between $19 and $21 apiece in its proposed initial public offering.

Citing a worsening U.S. growth and inflation outlook, Citi analysts have boosted their view of gold, saying the commodity could reach a record $3,600 an ounce over the next three months. A Citi team o ...

Friday’s drop in Treasury yields on concerns over a soft U.S. jobs report has taken them back to “a more positive level” for the stock market — at least for now, according to Sevens Report Research.

The audio streaming service said premium subscribers would be charged 11.99 euros ($13.89) a month starting in September, increasing from the prior monthly charge of 10.99 euros a month. The change ...

Shares of Praxis Precision Medicines jumped after the company announced positive topline results for a Phase 2 study of its seizure medication vormatrigine. The stock was up 15% at $62 in premarket ...